Quoin Pharmaceuticals (NASDAQ:QNRX) delivered the kind of interim clinical signal that can abruptly change the conversation around a small-cap biotech: its investigational QRX003 lotion produced statistically significant improvements in key measures of Netherton Syndrome in the first six patients to complete 12 weeks of treatment. The company says four of six participants, or 66.7%, achieved at least a one-grade improvement on the Investigator Global Assessment, producing a p=0.0087 result that cleared the study’s pre-specified interim alpha of 0.0215.